Treace Medical's Lapiplasty 3D Associated With Early Weightbearing After Foot Surgery, Interim Data Shows

Medical device company Treace Medical Concepts Inc TMCI has announced interim results from the ALIGN3D clinical study, a post-market 5-year study designed to evaluate outcomes of Lapiplasty 3D Bunion Correction in the surgical management of symptomatic hallux valgus.
Hallux valgus is the most common foot deformity.
Data were presented at the American College of Foot and Ankle Surgeons Annual Scientific Conference.
Data on the 128 study participants included in the interim analysis demonstrated:
- Early return to weight-bearing in a walking boot at an average of 8.3 days.
- Significant improvements in radiographic measurements of 3-dimensional bunion correction (hallux valgus angle, intermetatarsal angle, and tibial sesamoid position).
- 1.4% recurrence rate observed (1/72 patients) at 12 months post-surgery.
- Significant improvements in patient-reported pain reduction and quality of life measurements at six months were reported, maintained at 12 months post-procedure.
Final patient follow-up for the primary endpoint is anticipated in the first half of 2023.
Price Action: TMCI shares are down 1.81% at $29.82 during the market session on the last check Wednesday.